Treatment-related TEAEs reported
| . | HCT (n = 14) . | SOT (n = 12) . | All (N = 26) . |
|---|---|---|---|
| Abdominal pain∗ | 0 (0) | 4 (33.3) | 4 (15.4) |
| Abdominal distension | 0 (0) | 1 (8.3) | 1 (3.8) |
| Anemia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Colitis | 0 (0) | 1 (8.3) | 1 (3.8) |
| Dizziness | 1 (7.1) | 0 (0) | 1 (3.8) |
| Fatigue | 0 (0) | 1 (8.3) | 1 (3.8) |
| Febrile neutropenia | 0 (0) | 1 (8.3) | 1 (3.8) |
| General physical health deterioration | 1 (7.1) | 0 (0) | 1 (3.8) |
| GVHD in gastrointestinal tract | 1 (7.1) | 0 (0) | 1 (3.8) |
| GVHD in liver | 1 (7.1) | 0 (0) | 1 (3.8) |
| Hypocalcemia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Hyponatremia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Pneumonitis | 0 (0) | 1 (8.3) | 1 (3.8) |
| Pyrexia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Rash maculo-papular | 1 (7.1) | 0 (0) | 1 (3.8) |
| Tumor pain | 0 (0) | 1 (8.3) | 1 (3.8) |
| White blood cell count increased | 0 (0) | 1 (8.3) | 1 (3.8) |
| . | HCT (n = 14) . | SOT (n = 12) . | All (N = 26) . |
|---|---|---|---|
| Abdominal pain∗ | 0 (0) | 4 (33.3) | 4 (15.4) |
| Abdominal distension | 0 (0) | 1 (8.3) | 1 (3.8) |
| Anemia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Colitis | 0 (0) | 1 (8.3) | 1 (3.8) |
| Dizziness | 1 (7.1) | 0 (0) | 1 (3.8) |
| Fatigue | 0 (0) | 1 (8.3) | 1 (3.8) |
| Febrile neutropenia | 0 (0) | 1 (8.3) | 1 (3.8) |
| General physical health deterioration | 1 (7.1) | 0 (0) | 1 (3.8) |
| GVHD in gastrointestinal tract | 1 (7.1) | 0 (0) | 1 (3.8) |
| GVHD in liver | 1 (7.1) | 0 (0) | 1 (3.8) |
| Hypocalcemia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Hyponatremia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Pneumonitis | 0 (0) | 1 (8.3) | 1 (3.8) |
| Pyrexia | 0 (0) | 1 (8.3) | 1 (3.8) |
| Rash maculo-papular | 1 (7.1) | 0 (0) | 1 (3.8) |
| Tumor pain | 0 (0) | 1 (8.3) | 1 (3.8) |
| White blood cell count increased | 0 (0) | 1 (8.3) | 1 (3.8) |
Data are given as number (%).
Includes abdominal pain, abdominal discomfort, and abdominal pain lower.